SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    EASL Recommendations on Treatment of Hepatitis C 2015, Journal of Hepatology, 2015,

    CrossRef

  2. You have free access to this content2
    Masaru Enomoto, Hiroyasu Morikawa, Yoshiki Murakami, Akihiro Tamori, Norifumi Kawada, Adjuvant epoetin-β with peginterferon-α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2, Hepatology Research, 2014, 44, 10
  3. 3
    James F. Crismale, Valérie Martel-Laferrière, Kian Bichoupan, Emily Schonfeld, Alexis Pappas, Christina Wyatt, Joseph A. Odin, Lawrence U. Liu, Thomas D. Schiano, Ponni V. Perumalswami, Meena Bansal, Douglas T. Dieterich, Andrea D. Branch, Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy, Liver International, 2014, 34, 7
  4. 4
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  5. 5
    EASL Recommendations on Treatment of Hepatitis C 2014, Journal of Hepatology, 2014, 61, 2, 373

    CrossRef

  6. 6
    Zobair M. Younossi, Maria Stepanova, Linda Henry, Edward Gane, Ira M. Jacobson, Eric Lawitz, David Nelson, Lynn Gerber, Fatema Nader, Sharon Hunt, Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C, Clinical Gastroenterology and Hepatology, 2014, 12, 8, 1349

    CrossRef

  7. 7
    Jung-An Lin, Yeu-Chin Chen, Shin-Nan Cheng, Peng-Jen Chen, Heng-Cheng Chu, Tsai-Yuan Hsieh, Yu-Lueng Shih, Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan, Journal of the Formosan Medical Association, 2014, 113, 10, 727

    CrossRef

  8. 8
    Mark S. Sulkowski, Fred Poordad, Michael P. Manns, Jean-Pierre Bronowicki, K. Rajender Reddy, Stephen A. Harrison, Nezam H. Afdhal, Heather L. Sings, Lisa D. Pedicone, Kenneth J. Koury, Vilma Sniukiene, Margaret H. Burroughs, Janice K. Albrecht, Clifford A. Brass, Ira M. Jacobson, Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial, Hepatology, 2013, 57, 3
  9. 9
    Michelle Spaan, Zwier M.A. Groothuismink, Ludi Koning, Robert Roomer, Harry L.A. Janssen, Robert J. De Knegt, André Boonstra, Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients, Antiviral Research, 2013, 98, 3, 469

    CrossRef

  10. 10
    N. Gara, M. G. Ghany, What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin, Clinical Infectious Diseases, 2013, 56, 11, 1629

    CrossRef

  11. 11
    F. Stickel, B. Helbling, M. Heim, A. Geier, C. Hirschi, B. Terziroli, K. Wehr, A. De Gottardi, F. Negro, T. Gerlach, Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19, 2
  12. 12
    A. Birerdinc, M. Estep, A. Afendy, M. Stepanova, I. Younossi, A. Baranova, Z. M. Younossi, Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C), Journal of Viral Hepatitis, 2012, 19, 6
  13. 13
    Woo Jin Chung, Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients, Clinical and Molecular Hepatology, 2012, 18, 3, 268

    CrossRef

  14. 14
    Geert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, Bettina E Hansen, Yoav Lurie, Juan I Esteban, Martin Lagging, Francesco Negro, Stefan Zeuzem, Carlo Ferrari, Jean-Michel Pawlotsky, Avidan U Neumann, Solko W Schalm, Robert J de Knegt, Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study, BMC Gastroenterology, 2012, 12, 1, 11

    CrossRef

  15. 15
    Cara L. Mack, Regino P. Gonzalez-Peralta, Nitika Gupta, Daniel Leung, Michael R. Narkewicz, Eve A. Roberts, Philip Rosenthal, Kathleen B. Schwarz, NASPGHAN Practice Guidelines, Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 6, 838

    CrossRef

  16. 16
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2011, 55, 2, 245

    CrossRef

  17. 17
    Andrew H. Talal, Ruei-Chi Liu, Marija Zeremski, Rositsa Dimova, Lorna Dove, Daniel Pearce, Tarek Hassanein, Leleka Doonquah, David Aboulafia, Jorge Rodriguez, Hector Bonilla, Jeffrey Galpin, Judy A. Aberg, Barbara Johnston, Marshall J. Glesby, Ira M. Jacobson, Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/Hepatitis C Virus Patients Receiving Pegylated-Interferon and Ribavirin, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011, 58, 3, 261

    CrossRef

  18. 18
    Saumya Jayakumar, Vincent Bain, Rational Guide to the Use of Erythropoietin in the Treatment of HCV Infection, Current Hepatitis Reports, 2011, 10, 1, 62

    CrossRef

  19. 19
    W. J. Cash, K. Patterson, M. E. Callender, N. I. McDougall, Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients, Journal of Viral Hepatitis, 2010, 17, 4
  20. 20
    Patrice Cacoub, Philippe Halfon, Eric Rosenthal, François Bailly, Firouze Bani Sadr, Yves Benhamou, Stéphane Chevaliez, Jean Michel Pawlotsky, Lionel Piroth, Yazdan Yazdanpanah, Stanislas Pol, Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009, Journal of Hepatology, 2010, 53, 2, 230

    CrossRef

  21. 21
    Gaetano Bertino, Annalisa Ardiri, Patrizia Maria Boemi, Giuseppe Stefano Calvagno, Irene Maria Ruggeri, Annalisa Speranza, Maria Milena Santonocito, Dario Ierna, Cosimo Marcello Bruno, Maria Valenti, Roberta Boemi, Simona Naimo, Sergio Neri, Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis, European Journal of Clinical Pharmacology, 2010, 66, 10, 1055

    CrossRef

  22. 22
    Mark S. Sulkowski, Mitchell L. Shiffman, Nezam H. Afdhal, K. Rajender Reddy, Jonathan McCone, William M. Lee, Steven K. Herrine, Stephen A. Harrison, F. Fred Poordad, Kenneth Koury, Weiping Deng, Stephanie Noviello, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, 2010, 139, 5, 1602

    CrossRef

  23. 23
    Eric Chak, Sammy Saab, Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response, Current Hepatitis Reports, 2010, 9, 3, 147

    CrossRef

  24. 24
    Paul Y. Kwo, Rakesh Vinayek, The next step for taribavirin, Hepatology, 2010, 52, 4
  25. 25
    Fred Poordad, Eric Lawitz, Mitchell L. Shiffman, Tarek Hassanein, Andrew J. Muir, Bruce R. Bacon, Jamie Heise, Deanine Halliman, Eric Chun, Janet Hammond, Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C, Hepatology, 2010, 52, 4
  26. You have free access to this content26
    Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff, Diagnosis, management, and treatment of hepatitis C: An update, Hepatology, 2009, 49, 4
  27. 27
    S. Zeuzem, T. Berg, B. Moeller, H. Hinrichsen, S. Mauss, H. Wedemeyer, C. Sarrazin, D. Hueppe, E. Zehnter, M. P. Manns, Expert opinion on the treatment of patients with chronic hepatitis C, Journal of Viral Hepatitis, 2009, 16, 2
  28. 28
    Ayse L. Mindikoglu, Ram R. Miller, Hepatitis C in the Elderly: Epidemiology, Natural History, and Treatment, Clinical Gastroenterology and Hepatology, 2009, 7, 2, 128

    CrossRef

  29. 29
    Andrew Aronsohn, Nancy Reau, Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients, Journal of Clinical Gastroenterology, 2009, 43, 7, 661

    CrossRef

  30. 30
    Kuo-Chih Tseng, Li-Hsuan Chen, Chi-Yi Chen, Ting-Tsung Chang, An-Liang Chou, I-Chin Wu, Pin-Nan Cheng, Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b, Hepatology Research, 2009, 39, 6
  31. 31
    Hans L. Tillmann, Keyur Patel, John G. McHutchison, Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C, Current Gastroenterology Reports, 2009, 11, 1, 5

    CrossRef

  32. 32
    Fred F Poordad, Grace Chee, Taribavirin: a potential alternative to ribavirin, Future Virology, 2009, 4, 2, 113

    CrossRef

  33. 33
    H. PATEL, E. J. HEATHCOTE, When to treat and the benefits of treating hepatitis C in patients with haemophilia, Haemophilia, 2009, 15, 1
  34. 34
    Z. M. Younossi, F. H. Nader, C. Bai, R. Sjogren, J. P. Ong, R. Collantes, M. Sjogren, D. Farmer, L. Ramsey, K. Terra, H. Gujral, C. Gurung, M. Srishord, Y. Fang, A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment, Journal of Viral Hepatitis, 2008, 15, 5
  35. 35
    Andrew F. Shorr, John Doyle, Lee Stern, Margarita Dolgitser, Marya D. Zilberberg, Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications, Current Medical Research and Opinion, 2008, 24, 4, 1123

    CrossRef

  36. 36
    G. LARSSON, E.T. JANSON, Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life, European Journal of Cancer Care, 2008, 17, 2
  37. 37
    P. Cacoub, D. Sène, E. Rosenthal, S. Pol, Co-infection par le virus de l’immunodéficience humaine et le virus de l’hépatite C, Gastroentérologie Clinique et Biologique, 2008, 32, 3, S82

    CrossRef

  38. 38
    Naoki Hiramatsu, Nao Kurashige, Tsugiko Oze, Tetsuo Takehara, Shinji Tamura, Akinori Kasahara, Masahide Oshita, Kazuhiro Katayama, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Sumio Kawata, Hirohito Tsubouchi, Hiromitsu Kumada, Takeshi Okanoue, Shinichi Kakumu, Norio Hayashi, Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C, Hepatology Research, 2008, 38, 1
  39. 39
    Tatehiro Kagawa, Hirokazu Shiozawa, Sei-ichiro Kojima, Shinji Takashimizu, Naruhiko Nagata, Makoto Numata, Fumitoshi Morino, Yasuhiro Nishizaki, Kaori Mochizuki, Norihito Watanabe, Tetsu Watanabe, Shohei Matsuzaki, Tetsuya Mine, Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon α-2a in the treatment of chronic hepatitis C, Hepatology Research, 2008, 38, 3
  40. 40
    He-Jun Yuan, William M Lee, Nonresponse to Treatment for Hepatitis C, Drugs, 2008, 68, 1, 27

    CrossRef

  41. 41
    Mitchell L. Shiffman, Optimizing the Current Therapy for Chronic Hepatitis C Virus: Peginterferon and Ribavirin Dosing and the Utility of Growth Factors, Clinics in Liver Disease, 2008, 12, 3, 487

    CrossRef

  42. 42
    Eliana Z. Agudelo, Norah A. Terrault, Optimizing therapy in treatment-naïve genotype 1 patients, Current Hepatitis Reports, 2008, 7, 2, 64

    CrossRef

  43. 43
    Paul Martin, Donald M Jensen, Ribavirin in the treatment of chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2008, 23, 6
  44. 44
    M. Bourliere, Traitement de l’hépatite C : gestion des effets secondaires, Gastroentérologie Clinique et Biologique, 2008, 32, 5, S166

    CrossRef

  45. 45
    Jason P. Smith, Treatment Options for Patients with Hepatitis C: Role of Pharmacists in Optimizing Treatment Response and Managing Adverse Events, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008, 28, 9
  46. 46
    Thierry Thévenot, Jean-François Cadranel, Vincent Di Martino, Alexandre Pariente, Xavier Causse, Christophe Renou, Hervé Hagege, Jacques Denis, Françoise Lunel-Fabiani, A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C, Hepatology, 2007, 45, 2
  47. 47
    Sammy Saab, Mina K. Oh, Ayman B. Ibrahim, Francisco Durazo, Steven Han, Hasan Yersiz, Douglas G. Farmer, R. Mark Ghobrial, Leonard I. Goldstein, Myron J. Tong, Ronald W. Busuttil, Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C, Liver Transplantation, 2007, 13, 7
  48. 48
    Dominique Guyader, Comment traiter les malades non répondeurs à la bithérapie antivirale C ?, Gastroentérologie Clinique et Biologique, 2007, 31, 3, 317

    CrossRef

  49. 49
    Roberto J. Firpi, David R. Nelson, Current and Future Hepatitis C Therapies, Archives of Medical Research, 2007, 38, 6, 678

    CrossRef

  50. 50
    Jennifer L. Steel, Kapil Chopra, Marion C. Olek, Brian I. Carr, Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population, Quality of Life Research, 2007, 16, 2, 203

    CrossRef

  51. 51
    C. M. Behler, E. Vittinghoff, F. Lin, R. T. Chung, M. G. Peters, G. K. Robbins, P. A. Volberding, Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects, Clinical Infectious Diseases, 2007, 44, 10, 1375

    CrossRef

  52. 52
    Mitchell L. Shiffman, Marc G. Ghany, Timothy R. Morgan, Elizabeth C. Wright, Gregory T. Everson, Karen L. Lindsay, Anna S.F. Lok, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Jules L. Dienstag, David R. Gretch, Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C, Gastroenterology, 2007, 132, 1, 103

    CrossRef

  53. 53
    Stéphane Chevaliez, Jean-Michel Pawlotsky, Interferon-based therapy of hepatitis C, Advanced Drug Delivery Reviews, 2007, 59, 12, 1222

    CrossRef

  54. 54
    Brian Keefe, Interferon-induced depression in hepatitis C: An update, Current Psychiatry Reports, 2007, 9, 3, 255

    CrossRef

  55. 55
    Vito Di Marco, Piero Luigi Almasio, Donatella Ferraro, Vincenza Calvaruso, Giuseppe Alaimo, Sergio Peralta, Rosa Di Stefano, Antonio Craxì, Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial, Journal of Hepatology, 2007, 47, 4, 484

    CrossRef

  56. 56
    Patrice Cacoub, Lionel Piroth, Prise en charge des malades coinfectés VIH-VHC et VIH-VHB, Gastroentérologie Clinique et Biologique, 2007, 31, 10, 887

    CrossRef

  57. 57
    Stanislas Pol, Patrice Cacoub, Gilles Pialoux, Yves Benhamou, Philippe Halfon, Eric Rosenthal, Christian Perronne, Prise en charge des patients co-infectés VIH-VHC, Gastroentérologie Clinique et Biologique, 2007, 31, 8-9, 7

    CrossRef

  58. 58
    Thierry Fontanges, Sylvain Beorchia, Catherine Douvin, Patrick Delassalle, Jean-Marc Combis, Bertrand Hanslik, Jean-Paul Jacques, Bernard Filoche, Hervé Desmorat, Catherine Chandelier, Denis Ouzan, Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection, Gastroentérologie Clinique et Biologique, 2007, 31, 6-7, 566

    CrossRef

  59. 59
    Zobair Younossi, Jillian Kallman, John Kincaid, The effects of HCV infection and management on health-related quality of life, Hepatology, 2007, 45, 3
  60. 60
    Michael P. Manns, Graham R. Foster, Jürgen K. Rockstroh, Stefan Zeuzem, Fabien Zoulim, Michael Houghton, The way forward in HCV treatment — finding the right path, Nature Reviews Drug Discovery, 2007, 6, 12, 991

    CrossRef

  61. 61
    J.P. Zarski, V. Leroy, M.N. Hilleret, Tolérance et adhérence au traitement de l’hépatite C, Antibiotiques, 2007, 9, 4, 221

    CrossRef

  62. 62
    Mitchell L. Shiffman, Jennifer Salvatore, Sarah Hubbard, Angie Price, Richard K. Sterling, R. Todd Stravitz, Velimir A. Luketic, Arun J. Sanyal, Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha, Hepatology, 2007, 46, 2
  63. 63
    Norio Hayashi, Tetsuo Takehara, Antiviral therapy for chronic hepatitis C: past, present, and future, Journal of Gastroenterology, 2006, 41, 1, 17

    CrossRef

  64. 64
    Amrita Sethi, Mitchell L. Shiffman, Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response, Infectious Disease Clinics of North America, 2006, 20, 1, 115

    CrossRef

  65. 65
    Bruno Roche, Didier Samuel, Aspects of hepatitis C virus infection relating to liver transplantation, European Journal of Gastroenterology & Hepatology, 2006, 18, 4, 313

    CrossRef

  66. 66
    M. K. CHAPKO, J. A. DOMINITZ, Cost-effectiveness of growth factors during hepatitis C anti-viral therapy, Alimentary Pharmacology & Therapeutics, 2006, 24, 7
  67. 67
    John G. McHutchison, Michael P. Manns, Dan L. Longo, Definition and management of anemia in patients infected with hepatitis C virus, Liver International, 2006, 26, 4
  68. 68
    Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas Wise, Sean C. Robbins, Zobair M. Younossi, Depression, anemia and health-related quality of life in chronic hepatitis C, Journal of Hepatology, 2006, 44, 3, 491

    CrossRef

  69. 69
    Monika Homoncik, Wolfgang Sieghart, Elisabeth Formann, Monika Schmid, Peter Ferenci, Alfred Gangl, Bernd Jilma, Markus Peck-Radosavljevic, Erythropoietin Treatment Is Associated with More Severe Thrombocytopenia in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy, The American Journal of Gastroenterology, 2006, 101, 10, 2275

    CrossRef

  70. 70
    Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi, Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?, Journal of Hepatology, 2006, 44, 5, 837

    CrossRef

  71. 71
    Helen S. Yee, Sue L. Currie, Jama M. Darling, Teresa L. Wright, Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office, The American Journal of Gastroenterology, 2006, 101, 10, 2360

    CrossRef

  72. 72
    Jason E. Farley, David J. Dial, Marguerite Littleton-Kearney, Management of Hematologic and Neuropsychiatric Side Effects in Treatment of Chronic HCV Infection, The Journal for Nurse Practitioners, 2006, 2, 1, 38

    CrossRef

  73. 73
    R.J. Andrade, Manejo de los efectos adversos del tratamiento, Gastroenterología y Hepatología, 2006, 29, 184

    CrossRef

  74. 74
    Jason D. Graci, Craig E. Cameron, Mechanisms of action of ribavirin against distinct viruses, Reviews in Medical Virology, 2006, 16, 1
  75. 75
    Rudolf E. Stauber, Vanessa Stadlbauer, Novel approaches for therapy of chronic hepatitis C, Journal of Clinical Virology, 2006, 36, 2, 87

    CrossRef

  76. 76
    Jama M. Darling, Michael W. Fried, Optimizing Treatment Regimens in Hepatitis C, Clinics in Liver Disease, 2006, 10, 4, 835

    CrossRef

  77. 77
    Jean-Michel Pawlotsky, Therapy of hepatitis C: From empiricism to eradication, Hepatology, 2006, 43, S1
  78. 78
    Thierry Thevenot, Vincent Di Martino, Françoise Lunel-Fabiani, Claire Vanlemmens, Marie-Claude Becker, Jean-Pierre Bronowicki, Solange Bresson-Hadni, Jean-Philippe Miguet, Traitements complémentaires de l’hépatite chronique virale C, Gastroentérologie Clinique et Biologique, 2006, 30, 2, 197

    CrossRef

  79. 79
    Stefan Mauss, Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management, Journal of Hepatology, 2006, 44, S114

    CrossRef

  80. 80
    Amrita Sethi, Mitchell L. Shiffman, Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response, Clinics in Liver Disease, 2005, 9, 3, 453

    CrossRef

  81. 81
    Gregory M. Asnis, Richard De La Garza, Interferon-induced depression: Strategies in treatment, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 5, 808

    CrossRef

  82. 82
    Furqaan Ahmed, Ira M. Jacobson, Management of hematologic side effects: Impact on compliance and efficacy, Current Hepatitis Reports, 2005, 4, 2, 56

    CrossRef

  83. 83
    Mark S. Sulkowski, Management of the Hematologic Complications of Hepatitis C Therapy, Clinics in Liver Disease, 2005, 9, 4, 601

    CrossRef

  84. 84
    Glen Lutchman, Marc Ghany, Pushing the treatment envelope for chronic hepatitis C—is more necessarily better?, Hepatology, 2005, 41, 2
  85. 85
    Joji TOYOTA, Yosiyasu KARINO, Jun AKAIKE, Takumi OHMURA, Takahiro SATO, Katsu YAMAZAKI, Yasuaki KUWATA, Shiro IINO, Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon .ALPHA. plus ribavirin combination therapy, Kanzo, 2005, 46, 3, 107

    CrossRef

  86. 86
    Michael P. Curry, Nezam H. Afdhal, Use of Growth Factors with Antiviral Therapy for Chronic Hepatitis C, Clinics in Liver Disease, 2005, 9, 3, 439

    CrossRef

  87. 87
    Mitchell L. Shiffman, Cytopenias: How they Limit Therapy and Potential Correction,